Market Overview

Piper Jaffray Maintains Overweight on Arena Pharmaceuticals on Share Rally

Share:
Related ARNA
Jim Cramer Gives His Opinion On Allergan, USG And Arena Pharmaceuticals
22 Stocks Moving In Friday's Pre-Market Session

Piper Jaffray has published a research report on Arena Pharmaceuticals (NASDAQ: ARNA) commenting on the stock's 27% rise this week to date.

In the report, Piper Jaffray writes, "Shares of ARNA have risen 27% this week ahead of the company's June 27th PDUFA date for obesity drug Lorcaserin. We believe a lot of the volume has been driven by retail investors. Arena is one of the most heavily shorted stocks in our coverage universe with a ~22% short interest, so we could be seeing a squeeze. We maintain our Overweight rating pending the outcome of the June 27th PDUFA date, which will likely impact our current $7 price target."

Piper Jaffray maintains its Overweight rating and $7 price target on Arena Pharmaceuticals, which is currently trading down ~3.30% from yesterday's $7.88 closing price.

Latest Ratings for ARNA

DateFirmActionFromTo
Jul 2017CitigroupMaintainsBuy
Jun 2017CitigroupInitiates Coverage OnBuy
Jun 2017Cantor FitzgeraldInitiates Coverage OnOverweight

View More Analyst Ratings for ARNA
View the Latest Analyst Ratings

Posted-In: Piper JaffrayAnalyst Color Reiteration Analyst Ratings

 

Related Articles (ARNA)

View Comments and Join the Discussion!
Loading...
Loading...